Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00014222 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer
A Phase 3 study, sponsored by NCIC Clinical Trials Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,104
- Enrollment target
NCT00014222 is a Phase 3 study that has completed, run by NCIC Clinical Trials Group. The registered enrollment target is 2,104 participants.
The verdict
NCT00014222, a Phase 3 study, has completed, sponsored by NCIC Clinical Trials Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,104 participants
- Enrollment target
Study Summary
RATIONALE: 1. . To compare the effects on breast cancer of three different combinations of drugs which are commonly used to treat this disease. 2. . It is not yet known which treatment regimen is most effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy given with or without epoetin alfa in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer.
Interventions
- DRUG cyclophosphamide
- DRUG epirubicin hydrochloride
- BIOLOGICAL filgrastim
- DRUG doxorubicin hydrochloride
- BIOLOGICAL epoetin alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,104 participants |
| Start Date | 2000-12-04 |
| Est. Completion | 2014-03-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00014222
The ClinicalTrials.gov registry entry for NCT00014222 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NCIC Clinical Trials Group, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00014222 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00014222 about?
NCT00014222 is a clinical study titled "Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer". RATIONALE: 1. . To compare the effects on breast cancer of three different combinations of drugs which are commonly used to treat this disease. 2. . It is not yet known which treatment regimen is most effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of ...
What is the current status of trial NCT00014222?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,104 participants. The study started on 2000-12-04. Estimated completion is 2014-03-17.
What interventions are being tested in trial NCT00014222?
The interventions under investigation include: cyclophosphamide (DRUG), epirubicin hydrochloride (DRUG), filgrastim (BIOLOGICAL), doxorubicin hydrochloride (DRUG), epoetin alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT00014222?
This trial is sponsored by NCIC Clinical Trials Group, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.